Matt Miksic
Stock Analyst at Barclays
(3.90)
# 570
Out of 4,840 analysts
279
Total ratings
61.43%
Success rate
5.05%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LIVN LivaNova | Maintains: Equal-Weight | $56 → $55 | $42.02 | +30.91% | 7 | May 8, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $16 → $12 | $2.75 | +336.36% | 2 | May 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $90 → $93 | $84.54 | +10.01% | 6 | May 5, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $320.46 | -16.99% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $14.09 | +70.33% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $104.40 | +19.73% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $538.70 | +17.88% | 7 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $165 | $152.52 | +8.18% | 12 | Apr 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $158 → $159 | $130.83 | +21.53% | 29 | Apr 17, 2025 | |
| BAX Baxter International | Maintains: Overweight | $39 → $41 | $29.95 | +36.89% | 21 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $53 | $20.56 | +157.84% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $58.12 | +77.22% | 14 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $74.67 | +20.53% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $91.13 | +22.90% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $376.49 | +17.67% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $12.29 | +70.87% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.41 | +545.16% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $80.18 | +35.94% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $8.28 | +93.24% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $11.15 | +61.43% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $86.15 | +11.43% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $71.71 | +39.45% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $170.25 | +145.52% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $12.13 | +130.83% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $15.49 | +332.54% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $6.75 | +7,011.11% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.18 | +614.29% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.94 | +751.79% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.62 | +35.95% | 1 | Dec 12, 2016 |
LivaNova
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $42.02
Upside: +30.91%
Orchestra BioMed Holdings
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.75
Upside: +336.36%
DexCom
May 5, 2025
Maintains: Equal-Weight
Price Target: $90 → $93
Current: $84.54
Upside: +10.01%
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $320.46
Upside: -16.99%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $14.09
Upside: +70.33%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $104.40
Upside: +19.73%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $538.70
Upside: +17.88%
Johnson & Johnson
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $166 → $165
Current: $152.52
Upside: +8.18%
Abbott Laboratories
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $130.83
Upside: +21.53%
Baxter International
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $29.95
Upside: +36.89%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $20.56
Upside: +157.84%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $58.12
Upside: +77.22%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $74.67
Upside: +20.53%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $91.13
Upside: +22.90%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $376.49
Upside: +17.67%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $12.29
Upside: +70.87%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.41
Upside: +545.16%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $80.18
Upside: +35.94%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $8.28
Upside: +93.24%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $11.15
Upside: +61.43%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $86.15
Upside: +11.43%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $71.71
Upside: +39.45%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $170.25
Upside: +145.52%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $12.13
Upside: +130.83%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $15.49
Upside: +332.54%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $6.75
Upside: +7,011.11%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.18
Upside: +614.29%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.94
Upside: +751.79%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.62
Upside: +35.95%